Home / Health / Novo Nordisk: FDA Accepts For Review Class II Resubmissions For Tresiba …

Novo Nordisk: FDA Accepts For Review Class II Resubmissions For Tresiba …

Novo Nordisk (NVO: Quote) pronounced that a US Food and Drug Administration has supposed for examination a Class II Resubmissions for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart).

To safety a firmness of a ongoing DEVOTE trial, usually a tiny group within Novo Nordisk has entrance to a data. This group has prepared a halt research for a Class II resubmission and will correlate with a FDA during a review, on matters associated to a halt analysis.

As formerly indicated, a outcome of an halt research carries a aloft turn of doubt than a final investigate formula as this rough guess is built on a almost reduce series of observations. Accordingly, a relations risk guess subsequent from a halt research is so usually an denote of a final hearing results.

Novo Nordisk government does not have entrance to a formula of a halt analysis. The hearing is approaching to be finished in a second half of 2016.

by RTT Staff Writer

For comments and feedback: [email protected]

Business News

Article source: http://www.rttnews.com/2479576/novo-nordisk-fda-accepts-for-review-class-ii-resubmissions-for-tresiba-ryzodeg.aspx

Scroll To Top